GlaxoSmithKline's Pay-for-Delay Settlement and COPD Patients
Breo Ellipta, GlaxoSmithKline's fixed-dose combination inhaler containing fluticasone furoate and vilanterol for COPD and asthma, has been the subject of antitrust litigation alleging GSK engaged in pay-for-delay (reverse payment) agreements with generic manufacturers to suppress competition and maintain Breo's high branded price for longer than patent law warranted. Pay-for-delay cases became more viable after the Supreme Court's 2013 ruling in FTC v. Actavis, which held that reverse payment settlements can violate antitrust law and are subject to rule of reason analysis.
The pay-for-delay theory: pharmaceutical patent holders pay potential generic competitors to delay their market entry in exchange for settlement of patent litigation, even when the generic would have won the underlying patent challenge. This arrangement harms consumers who pay higher branded prices longer than they would in a competitive market. Consulting pharmaceutical antitrust attorneys can help evaluate your specific claim. COPD patients who paid branded Breo prices while generic equivalents were allegedly being suppressed by settlement arrangements are the core class members in antitrust class actions against GSK.
How Pay-for-Delay Works in the Drug Market
Generic manufacturers file Abbreviated New Drug Applications (ANDAs) asserting that their generic product is bioequivalent to the branded drug and that the branded drug's patents are invalid or not infringed. The patent holder has 45 days to file an infringement lawsuit, which automatically triggers a 30-month stay of FDA approval for the generic. Facing this stay, generic manufacturers sometimes settle, accepting delayed entry in exchange for payments, licenses, or other value from the branded manufacturer. The FTC and private plaintiffs argue these settlements harm consumers by maintaining the branded price floor longer than competition would otherwise require. Related: other pharmaceutical market competition issues.
How to File a Claim or Get Help
If you believe you qualify based on the eligibility criteria outlined above, the next step is a free consultation with an experienced attorney who handles this case type. Most plaintiff-side attorneys offer no-cost initial evaluations and work on contingency, meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation to your consultation: receipts, medical records, correspondence, or any evidence of the harm you experienced.
To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to the LawsuitWatch newsletter. We update our coverage as new court filings, settlement announcements, and eligibility changes are made public.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Breo Ellipta Lawsuit 2026: What You Need to Know: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What is a pay-for-delay agreement in pharmaceuticals?
A pay-for-delay agreement (also called a reverse payment settlement) occurs when a brand drug manufacturer pays a generic competitor to drop its patent challenge and delay its market entry. The FTC argues these arrangements harm consumers by preserving artificially high branded prices. The Supreme Court held in 2013 that they are subject to antitrust scrutiny under the rule of reason.
Who can join the Breo Ellipta class action?
The class typically covers third-party payers (insurance companies, employer health plans, union health funds) and individual consumers who paid for branded Breo Ellipta at prices above what would have prevailed in a competitive market with timely generic entry. The overcharge during the suppression period is the core damages calculation.
How much more expensive is branded Breo than generics?
Branded inhalers like Breo Ellipta typically cost $350–$500 per month without insurance. When generics enter the market, prices can drop 80–90%. For COPD patients who rely on daily inhaler use, the difference between branded and generic pricing represents thousands of dollars annually. This overcharge over the alleged suppression period constitutes the class damages.
Has GSK settled pay-for-delay cases before?
GSK and other major pharmaceutical manufacturers have settled multiple pay-for-delay antitrust cases. Settlements have ranged from tens of millions to over a billion dollars in total antitrust class actions against major manufacturers. Each drug and settlement period is distinct; prior GSK settlements don't automatically resolve Breo-specific claims.
What is the status of the Breo Ellipta antitrust lawsuit?
For the current status of Breo Ellipta pay-for-delay litigation, search PACER for active cases and any settlement notices. Pharmaceutical antitrust cases typically take 4-7 years from filing to final settlement distribution. Check antitrust class action settlement websites and consumer protection attorney updates for current information.
Legal Disclaimer
This article is for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Lawsuit eligibility, settlement amounts, and case status are subject to change as litigation develops. Always consult a licensed attorney in your jurisdiction before making legal decisions. LawsuitWatch is an independent journalism publication and is not a law firm. LawsuitWatch may receive referral compensation from affiliated legal service providers, which does not influence editorial content.